ESR1 and breast carcinoma: SERENA-3 (NCT04588298) is investigating the effects of 5–7 days’ treatment with 3 different doses of camizestrant on ER H-scores and Ki67 in 132 women with ER+/HER2− primary breast cancer [20, 21].